As ordered reported by the House Committee on Energy and Commerce on July 15, 2014
H.R. 594 would amend the Public Health Service Act to reauthorize surveillance, research, and education activities relating to muscular dystrophy. The bill would expand the portfolios of the National Institutes of Health (NIH) and the Centers for Disease Control and Prevention (CDC) to include additional forms of muscular dystrophy. It also would direct CDC to capture more representative data regarding muscular dystrophy across populations.
CBO estimates that implementing H.R. 594 would cost $323 million over the 2015-2019 period, assuming appropriation of the necessary amounts. Pay-as-you-go procedures do not apply to this legislation because it would not affect direct spending or revenues.
H.R. 594 contains no intergovernmental and private-sector mandates as defined in the Unfunded Mandates Reform Act.